A carregar...
Targeted Therapies: The Rare Cancer Paradigm
This review analyzes the state of the art of targeted therapies for several tumors, starting from the paradigmatic example of Imatinib treatment in chronic myelogenous leukemia (CML). We discuss how rare tumors can be models for various mechanisms of receptor tyrosine kinase (RTK) activation, and pr...
Na minha lista:
| Publicado no: | Mol Oncol |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2009
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5527958/ https://ncbi.nlm.nih.gov/pubmed/19913465 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molonc.2009.10.003 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|